Bing V Chen

US Patent:

8244669, Aug 14, 2012

Filed:

Dec 30, 2008

Appl. No.:

12/346748

Inventors:

Deanna Ellis - Pasadena CA, US
Bing Chen - Glendale CA, US

Assignee:

Blackboard Connect Inc. - Washington DC

International Classification:

G06F 17/30

US Classification:

707609, 707613, 707623, 709223, 709226

Abstract:

A method for determining membership in a group of notification recipients and issuing a notification to the group of notification recipients, is disclosed. The method includes associating a set of potential recipients of notifications with at least one descriptor and dynamically forming a group of recipients to receive at least one notification based on the descriptors currently associated with the set of potential recipients of notifications. The method also includes issuing the at least one notification to the group of recipients. A system for determining membership in a group of notification recipients and issuing a notification to the group of notification recipients, is also provided.

US Patent:

20090217401, Aug 27, 2009

Filed:

May 2, 2006

Appl. No.:

11/913217

Inventors:

Alan J. Korman - Piedmont CA, US
Mohan Srinivasan - San Jose CA, US
Changyu Wang - Fremont CA, US
Mark J. Selby - San Francisco CA, US
Bing Chen - Alameda CA, US
Josephine M. Cardarelli - San Carlos CA, US

Assignee:

MEDAREX, INC - Princeton NJ

International Classification:

A01K 67/027
A61K 39/395
C07H 21/00
C12N 15/74
C12N 5/10
C12N 5/16
C07K 16/18
A61P 35/00

US Classification:

800 18, 53038815, 4241421, 536 2353, 4353201, 435325, 435326, 530402

Abstract:

The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.

US Patent:

20100162364, Jun 24, 2010

Filed:

Dec 24, 2008

Appl. No.:

12/344112

Inventors:

Joshua ROTH - Pacific Palisades CA, US
Bing CHEN - Glendale CA, US

Assignee:

BLACKBOARD CONNECT INC. - Washington DC

International Classification:

G06F 21/00

US Classification:

726 4

Abstract:

A method for determining access privileges for transmitting mass notifications, is disclosed. The method includes storing information regarding user-level access privileges of a group to transmit a notification. The user group includes a user that inherits the user-level access privileges of the user group. The method also includes storing information regarding administrator-level access privileges of an administrator group, and permitting access to transmit the notification by the user based on the user's access privileges, the at least one notification, and the at least one recipient. The administrator group includes an administrator that inherits the administrator-level access privileges. The administration module is configurable by the administrator based on the administrator's access privileges. A system for determining access privileges for transmitting mass notifications is also provided.

US Patent:

20130133091, May 23, 2013

Filed:

Aug 15, 2011

Appl. No.:

13/210137

Inventors:

Alan J. Korman - Piedmont CA, US
Mohan Srinivasan - San Jose CA, US
Changyu Wang - Fremont CA, US
Mark J. Sellby - San Francisco CA, US
Bing Chen - Alameda CA, US
Josephine M. Cardarelli - San Carlos CA, US
Haichun Huang - San Carlos CA, US

Assignee:

Ono Pharmaceutical Co., LTD. - Osaka
Medarex, Inc. - Princeton NJ

International Classification:

C07K 16/18

US Classification:

800 18, 4353201, 435332, 435 696, 536 2353

Abstract:

The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.